The American Journal of Managed Care

Prophylactic Treatment Challenges and Considerations for Hemophilia A

Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...
Morningstar

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Treatment Considerations Additional survey results indicate a need for more frequent and transparent conversations around treatment options, with 65% of patients surveyed feeling like they still haven ...
Healio

Concizumab prophylaxis significantly reduces bleeding events for people with hemophilia

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody significantly reduced both treated spontaneous and traumatic bleeds among individuals ...
Medscape

Prophylaxis Against PJP in ANCA-Associated Vasculitis Also Cuts Risk for Other Serious Infections

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...
Healio

Fitusiran prophylaxis superior to on-demand treatment for severe hemophilia

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...
Seeking Alpha

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

- Ionis’ second independent launch in just nine months, with potential for two additional launches next year - - Ionis to host webcast today at 12:15pm ET - CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis ...
The American Journal of Managed Care

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

The COCOON trial assessed prophylactic dermatologic regimens in NSCLC patients treated with amivantamab and lazertinib, showing reduced AEs and improved quality of life. Prophylactic treatment ...